Hepatobiliary system and intestinal injury in new coronavirus infection (COVID-19): A retrospective study

Table 1 Changes of alanine aminotransferase, aspartate aminotransferase and serum bilirubin in patients with coronavirus disease 19 compared with the control group, depending on the severity of the disease

Indication	COVID-19 patients (n = 80)	Control Group (n = 17)	P value	COVID-19-patients, mild severity (n = 19)	COVID-19-patients, moderate severity (n = 61)	P value
ALT, IU/L	75 (21-96)	21 (5-30)	< 0.05	57 (16-65)	89 (79-96)	< 0.05
AST, IU/L	81 (26-112)	26 (8-35)	< 0.05	60 (20-69)	102 (90;112)	< 0.05
Total bilirubin, µmol /L	63.2 (13.8-70.2)	22.1 (5.4-25.3)	< 0.05	41.3 (22.8-62.1)	72.4 (35.2-89.2)	< 0.05

Compared with control group, patients with COVID-19 had increased level of ALT (35; 43.7%), AST (45; 56.2%) and total bilirubin (32; 39.4%). COVID-19: Coronavirus disease 19; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.